Harmony Biosciences Holdings (HRMY) Net Margin (2020 - 2026)

Harmony Biosciences Holdings has disclosed Net Margin across 7 years of filings, most recently posting 15.08% for Q1 2026.

• Net Margin for Q1 2026 came in at 15.08%, down 958.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 17.82% (down 664.0% YoY), and the FY2025 annual result was 19.96%, down 452.0% from the prior year.
• Net Margin came in at 15.08% for Q1 2026 at Harmony Biosciences Holdings, down from 15.22% in the prior quarter.
• In the past five years, Net Margin ranged from a high of 75.03% in Q3 2022 to a low of 29.18% in Q4 2022.
• The 5-year median for Net Margin is 24.0% (2023), against an average of 22.04%.
• Peak annual rise in Net Margin reached 8695 bps in 2022, while the deepest fall reached 5408 bps in 2022.
• Harmony Biosciences Holdings' Net Margin stood at 29.18% in 2022, then surged by 154 bps to 15.8% in 2023, then jumped by 148 bps to 39.22% in 2024, then slumped by 61 bps to 15.22% in 2025, then dropped by 1 bps to 15.08% in 2026.
• The last three Net Margin figures came in at 15.08% (Q1 2026), 15.22% (Q4 2025), and 21.24% (Q3 2025), per Business Quant data.